DK2802325T3 - ANESTHETIC RELATIONS AND RELATED APPLICATIONS THEREOF - Google Patents

ANESTHETIC RELATIONS AND RELATED APPLICATIONS THEREOF Download PDF

Info

Publication number
DK2802325T3
DK2802325T3 DK13735638.2T DK13735638T DK2802325T3 DK 2802325 T3 DK2802325 T3 DK 2802325T3 DK 13735638 T DK13735638 T DK 13735638T DK 2802325 T3 DK2802325 T3 DK 2802325T3
Authority
DK
Denmark
Prior art keywords
optionally substituted
etomidate
compound
branched
minutes
Prior art date
Application number
DK13735638.2T
Other languages
Danish (da)
English (en)
Inventor
Douglas E Raines
Syed Shaukat Husain
John C R Randle
Original Assignee
Massachusetts Gen Hospital
Annovation Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Gen Hospital, Annovation Biopharma Inc filed Critical Massachusetts Gen Hospital
Application granted granted Critical
Publication of DK2802325T3 publication Critical patent/DK2802325T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Anesthesiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
DK13735638.2T 2012-01-13 2013-01-11 ANESTHETIC RELATIONS AND RELATED APPLICATIONS THEREOF DK2802325T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261586450P 2012-01-13 2012-01-13
US201261622627P 2012-04-11 2012-04-11
PCT/US2013/021245 WO2013106717A1 (en) 2012-01-13 2013-01-11 Anesthetic compounds and related methods of use

Publications (1)

Publication Number Publication Date
DK2802325T3 true DK2802325T3 (en) 2017-03-13

Family

ID=48781947

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13735638.2T DK2802325T3 (en) 2012-01-13 2013-01-11 ANESTHETIC RELATIONS AND RELATED APPLICATIONS THEREOF

Country Status (24)

Country Link
US (4) US9156825B2 (enExample)
EP (2) EP2802325B1 (enExample)
JP (1) JP6196986B2 (enExample)
CN (2) CN104168899B (enExample)
AU (1) AU2013207811B2 (enExample)
BR (1) BR112014017230A2 (enExample)
CA (1) CA2861071C (enExample)
CY (1) CY1118842T1 (enExample)
DK (1) DK2802325T3 (enExample)
EA (1) EA027976B1 (enExample)
ES (1) ES2617536T3 (enExample)
HR (1) HRP20170330T1 (enExample)
HU (1) HUE030892T2 (enExample)
IN (1) IN2014DN06132A (enExample)
LT (1) LT2802325T (enExample)
NZ (1) NZ627274A (enExample)
PL (1) PL2802325T3 (enExample)
PT (1) PT2802325T (enExample)
RS (1) RS56025B1 (enExample)
SG (1) SG11201403980VA (enExample)
SI (1) SI2802325T1 (enExample)
SM (1) SMT201700145T1 (enExample)
WO (1) WO2013106717A1 (enExample)
ZA (1) ZA201405248B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3360863B1 (en) * 2015-10-10 2022-04-20 Jiangsu Nhwaluokang Pharmaceutical Research and Development Co., Ltd. Etomidate derivative and intermediate, preparation method and use thereof
CN105663042A (zh) * 2016-02-03 2016-06-15 北京蓝丹医药科技有限公司 一种稳定的麻醉药物脂肪乳及其制备方法
CN107382870A (zh) * 2016-05-17 2017-11-24 四川海思科制药有限公司 N‑取代咪唑羧酸酯类化合物及其制备方法和在医药上的用途
CN107445898A (zh) * 2016-05-30 2017-12-08 四川海思科制药有限公司 N‑取代咪唑羧酸酯类化合物及其制备方法和在医药上的用途
CN107522662A (zh) * 2016-06-16 2017-12-29 四川海思科制药有限公司 N‑取代咪唑羧酸酯类化合物及其制备方法和在医药上的用途
CN107641105A (zh) * 2016-07-22 2018-01-30 四川海思科制药有限公司 N‑取代咪唑羧酸酯类化合物及其制备方法和在医药上的用途
CN106432163A (zh) * 2016-09-29 2017-02-22 山东东方农药科技实业有限公司 一种螺环内酯类化合物、其合成方法以及其用途
CN107652239B (zh) * 2017-02-24 2020-08-04 四川大学华西医院 N-取代咪唑羧酸酯类化合物、制备方法及用途
CN109776511B (zh) * 2018-01-30 2023-10-27 成都麻沸散医药科技有限公司 一种n-取代咪唑甲酸酯类衍生物及其用途
CN109053410A (zh) * 2018-08-06 2018-12-21 兰博尔开封科技有限公司 一种合成1-羟基环己基甲酸的新工艺及应用
KR20210066833A (ko) 2018-09-26 2021-06-07 지앙수 헨그루이 메디슨 컴퍼니 리미티드 엑사테칸 유사체의 리간드-약물 접합체, 이를 위한 제조 방법, 및 이의 적용
WO2020063673A1 (zh) 2018-09-30 2020-04-02 江苏恒瑞医药股份有限公司 抗b7h3抗体-依喜替康类似物偶联物及其医药用途
CN109761906B (zh) * 2019-03-02 2023-08-11 成都麻沸散医药科技有限公司 一种取代咪唑甲酸酯类衍生物及其用途
CN110003188B (zh) * 2019-03-27 2022-08-26 成都麻沸散医药科技有限公司 取代吡咯甲酸酯类衍生物及其用途
JP7467610B2 (ja) 2019-09-18 2024-04-15 バイリ－バイオ（チェンドゥ）ファーマスーティカル シーオー．，エルティーディー． カンプトテシン誘導体及びその複合体
JP2022551176A (ja) * 2019-10-11 2022-12-07 成都麻沸散医薬科技有限公司 置換窒素複素環化合物およびその麻酔作用
CN110669017B (zh) * 2019-10-11 2023-08-04 成都麻沸散医药科技有限公司 多取代三唑甲酸酯类衍生物及其用途
CN112174890B (zh) * 2020-10-09 2022-05-27 成都麻沸散医药科技有限公司 酮取代杂环化合物及其麻醉作用
CN114650845B (zh) 2019-12-12 2024-04-16 江苏恒瑞医药股份有限公司 抗密蛋白抗体药物偶联物及其医药用途
UA129521C2 (uk) 2019-12-16 2025-05-21 Джянгсу Хенгруй Медісін Ко., Лтд. Аналог кон'югата анти-сеа антитілo-ексатекан та його фармацевтичне застосування
CA3168654A1 (en) 2020-01-22 2021-07-29 Shanghai Senhui Medicine Co., Ltd. Drug conjugate of eribulin derivative, preparation method therefor and application thereof in medicine
CN118787756A (zh) 2020-01-22 2024-10-18 江苏恒瑞医药股份有限公司 抗trop-2抗体-依喜替康类似物偶联物及其医药用途
JP7730836B2 (ja) 2020-03-25 2025-08-28 江蘇恒瑞医薬股▲ふん▼有限公司 抗体薬物複合体の調製方法
JP7689979B2 (ja) 2020-03-25 2025-06-09 江蘇恒瑞医薬股▲ふん▼有限公司 抗体薬物複合体を含む医薬組成物及びその使用
US20230140397A1 (en) 2020-03-25 2023-05-04 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-psma antibody-exatecan analogue conjugate and medical use thereof
AU2022316425A1 (en) 2021-07-22 2024-02-01 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Drug conjugate of eribulin derivative
WO2023116861A1 (zh) 2021-12-23 2023-06-29 江苏恒瑞医药股份有限公司 抗dll3抗体、其抗体-药物偶联物及其医药用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3354173A (en) 1964-04-16 1967-11-21 Janssen Pharmaceutica Nv Imidazole carboxylates
US3270960A (en) 1964-09-11 1966-09-06 Sperry Rand Corp Fluid sensor
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CA1066709A (en) 1975-03-10 1979-11-20 Walter A.M. Helsen Preparation of loweralkyl imidazole carboxylates
US4038286A (en) 1975-03-10 1977-07-26 Janssen Pharmaceutica N.V. Racemates and optical isomers of 1-(1-phenylethyl)-1h-imidazole-5-carboylic acid derivatives
GR64915B (en) 1978-09-14 1980-06-09 Janssen Pharmaceutica Nv Improved etomidate-containing compositions
EP0277384A3 (en) 1986-12-24 1990-05-23 Janssen Pharmaceutica N.V. 1h-imidazole-5-carboxylic acid derivatives
US4878940A (en) 1987-04-02 1989-11-07 Janssen Pharmaceutica N.V. Herbicidal 1,5-substituted 1H-imidazoles
AU629290B2 (en) 1989-01-31 1992-10-01 Merrell Dow Pharmaceuticals Inc. Novel aryl-or heteroaryl-1-alkyl-pyrrole-2-carboxylic acid compounds useful in treating interleukin-1 mediated conditions
US5041554A (en) 1989-01-31 1991-08-20 Merrell Dow Pharmaceuticals Inc. Novel aryl-or heteroaryl-1-alkyl-pyrrole-2-carboxylic acid compounds useful in treating interleukin-1 mediated conditions
US5019583A (en) 1989-02-15 1991-05-28 Glaxo Inc. N-phenyl-N-(4-piperidinyl)amides useful as analgesics
US5242939A (en) 1990-09-28 1993-09-07 Warner-Lambert Company Anilide derivatives with angiotensin ii antagonist properties
JP3374922B2 (ja) 1991-05-09 2003-02-10 日産化学工業株式会社 複素環式第３級アミンの製造方法
JPH06345728A (ja) 1993-06-11 1994-12-20 Nissan Chem Ind Ltd Ｎ−置換アゾール誘導体の製造方法
US5466700A (en) 1993-08-30 1995-11-14 Glaxo Wellcome Inc. Anesthetic use of N-phenyl-N-(4-piperidinyl)amides
US5997898A (en) 1995-06-06 1999-12-07 Imarx Pharmaceutical Corp. Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery
US5756528A (en) 1995-06-06 1998-05-26 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US20030055023A1 (en) 2001-03-20 2003-03-20 Rajewski Roger A. Formulations containing etomidate and a sulfoalkyl ether cyclodextrin
US6897319B2 (en) 2001-12-27 2005-05-24 Ortho-Mcneil Pharmaceutical, Inc. Useful aroyl pyrrole heteroaryl methanones and methanols
US20080206138A1 (en) 2003-08-06 2008-08-28 Ilse Zolle Radiolabelled Phenylethyl Imidazole Carboxylic Acid Ester Derivatives
US7189859B2 (en) 2003-08-06 2007-03-13 Ilse Zolle Radiolabelled phenylethyl imidazole carboxylic acid ester derivatives
EP1778652A2 (en) 2004-08-20 2007-05-02 EntreMed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
US7592362B2 (en) * 2006-01-19 2009-09-22 Pfizer Limited Substituted imidazoles
EP1982716B1 (en) 2006-01-24 2013-04-03 Nippon Zoki Pharmaceutical Co. Ltd. Novel histidine derivative
WO2007144725A2 (en) 2006-06-09 2007-12-21 Ge Healthcare Limited SYNTHESIS AND EVALUATION OF 18F-LABELLED ALKYL-1-[(R)-1-PHENYLETHYL]-1H-IMIDAZOLE-5-CARBOXYLATE AS A TRACER FOR THE QUANTIFICATION OF β-11-HYDROXYLASE ENZYME IN THE ADRENAL GLANDS
WO2009014097A1 (ja) 2007-07-23 2009-01-29 Nippon Zoki Pharmaceutical Co., Ltd. 新規ヒスチジン誘導体
EP2271627A4 (en) 2008-03-31 2012-04-11 Gen Hospital Corp ETOMIDATE ANALOGUE WITH IMPROVED PHARMACOKINETIC AND PHARMACODDYNAMIC PROPERTIES
CA2767112C (en) * 2009-07-10 2018-06-19 The General Hospital Corporation Etomidate analogues that do not inhibit adrenocortical steroid synthesis

Also Published As

Publication number Publication date
US9820971B2 (en) 2017-11-21
US9156825B2 (en) 2015-10-13
CN107382812A (zh) 2017-11-24
JP6196986B2 (ja) 2017-09-13
HRP20170330T1 (hr) 2017-04-21
US10154991B2 (en) 2018-12-18
CN104168899B (zh) 2017-04-05
SI2802325T1 (sl) 2017-04-26
CA2861071A1 (en) 2013-07-18
EP2802325B1 (en) 2016-11-30
EA027976B1 (ru) 2017-09-29
HUE030892T2 (hu) 2017-07-28
PL2802325T3 (pl) 2017-11-30
US20150328189A1 (en) 2015-11-19
CY1118842T1 (el) 2018-01-10
CN104168899A (zh) 2014-11-26
US20150203476A1 (en) 2015-07-23
SMT201700145T1 (it) 2017-05-08
LT2802325T (lt) 2017-03-10
BR112014017230A2 (pt) 2020-11-24
ES2617536T3 (es) 2017-06-19
EP3184512B1 (en) 2020-12-23
US20180098968A1 (en) 2018-04-12
NZ627274A (en) 2015-10-30
SG11201403980VA (en) 2014-08-28
EP2802325A4 (en) 2015-06-10
EA201491362A1 (ru) 2014-12-30
WO2013106717A1 (en) 2013-07-18
IN2014DN06132A (enExample) 2015-08-14
EP3184512A1 (en) 2017-06-28
EP2802325A1 (en) 2014-11-19
ZA201405248B (en) 2017-04-26
US9522136B2 (en) 2016-12-20
PT2802325T (pt) 2017-03-01
AU2013207811B2 (en) 2017-08-10
US20170273951A1 (en) 2017-09-28
RS56025B1 (sr) 2017-09-29
CA2861071C (en) 2017-09-12
AU2013207811A1 (en) 2014-07-31
JP2015508415A (ja) 2015-03-19

Similar Documents

Publication Publication Date Title
DK2802325T3 (en) ANESTHETIC RELATIONS AND RELATED APPLICATIONS THEREOF
CN102548964B (zh) 不抑制肾上腺皮质类固醇合成的依托咪酯类似物
MX2010010675A (es) Analogos de etomidato con propiedades farmacocineticas y farmacodinamicas mejoradas.
KR101285645B1 (ko) 진통제
HK1240228B (en) Anesthetic compounds and related methods of use
HK1240228A1 (en) Anesthetic compounds and related methods of use
HK1172026B (en) Etomidate analogues that do not inhibit adrenocortical steroid synthesis